Therapy for sleep, medicine for sleep, or both?

Why this guideline was needed

Chronic insomnia disorder, trouble falling asleep, staying asleep, or waking too early, with real effects the next day, affects roughly 10 to 15 percent of adults. Care has long run on two tracks. One is CBT-I, cognitive behavioral therapy for insomnia, a structured program that works on the habits and thoughts that keep sleep broken. The other is prescription medication. Professional guidance covered each track on its own, in 2017 for medicines and in 2021 for behavioral treatment, where CBT-I earned a strong recommendation. In practice, though, the tracks are often combined from the start, and nobody had graded that choice.

Two recommendations, one clear order

The 2026 guideline makes two recommendations, and together they form a ranking. First, it suggests combination treatment, CBT-I plus medication, over medication alone. Second, it suggests against combination treatment over CBT-I alone. So the order is CBT-I alone at the top, the combination next, and medication alone at the bottom. Both recommendations are conditional rather than strong, and the evidence behind both is rated low certainty. That pairing is the honest core of the document: the direction looks consistent, and the panel is open that the underlying trials are few and imperfect.

What combined treatment actually added

Against medication alone, the evidence came from six randomized trials in seven articles. The combination improved overall insomnia severity and sleep continuity by amounts the panel judged clinically meaningful, though the effects were small. Daytime symptoms leaned toward the combination without reaching the meaningful mark, total sleep time did not meaningfully improve, and the combination group reported slightly more morning sleepiness. Against CBT-I alone, also six trials in seven articles, the combination added no clinically meaningful gain in severity, continuity, or daytime symptoms. Total sleep time rose by a meaningful amount, but the confidence interval included zero, so even that gain is not firmly established.

Where patient preference changes the answer

The guideline writes its own exception. A patient who values more total sleep early in treatment above other outcomes, or who cares less about daytime symptom relief, may reasonably pick the combination over CBT-I alone. That is not a loophole. It is how conditional recommendations are meant to work: the panel sets the default, and the patient's priorities can move it. Access matters too. The panel notes that where CBT-I is unavailable or unaffordable, a recommendation built on it can widen gaps in care, and it urges clinicians to make CBT-I easier to reach, including by telehealth and digital programs, while being honest that those formats have their own dropout problems.

What this means if you are in treatment here

Combined care is the setting this practice works in, and this guideline sharpens how the two halves should be weighed. Therapy for insomnia is not a softer substitute for medication. On current evidence it is the stronger half, and medication earns its place as an addition for a defined reason, such as early total sleep, rather than as the plan itself. If you are on a sleep medicine and have never been offered CBT-I, that gap is worth raising. If you are in CBT-I and sleeping a little more but still struggling in the day, that pattern is worth raising too, because the guideline's daytime findings cut in a direction many patients do not expect.

The short version

Start with CBT-I where it is available. Add medication to it only for a reason you and your clinician can name. Do not settle for medication alone if a behavioral program is within reach, because that arrangement performed worst in the comparisons. And hold the whole ranking lightly: the panel graded its own evidence low certainty, studied only treatments started together, and left the common question of adding one treatment later largely unanswered.

Sources

Everything in this article traces back to the sources below. Ratings and figures are the guideline's own.

Buysse and colleagues, Journal of Clinical Sleep Medicine (2026): the American Academy of Sleep Medicine clinical practice guideline on combination treatment for chronic insomnia disorder in adults, based on a systematic review using the GRADE process, with the evidence search completed in June 2025. Journal of Clinical Sleep Medicine.

American Academy of Sleep Medicine (2026): the guideline at a glance summary, listing both recommendations and the exception the guideline itself sets out for patients who value more total sleep early in treatment. AASM guideline at a glance.

Edinger and colleagues, Journal of Clinical Sleep Medicine (2021): the earlier AASM guideline on behavioral and psychological treatments for chronic insomnia, which gave multicomponent CBT-I its strong recommendation. PubMed record.

Please read this part

This article is educational and is not medical advice. It does not create a treatment relationship. Guidelines summarize group results, and insomnia usually travels with other conditions, including depression, anxiety, pain, and sleep apnea, that change what treatment should look like. Do not start, stop, or change a sleep medicine because of anything here. Raise it with your clinician, who can weigh the guideline against your situation.

If you are having thoughts of harming yourself, help is available now: call or text 988, text HOME to 741741 for Crisis Text Line, or call the NAMI Helpline at 1-800-950-6264. This practice is not an emergency service. If someone is in immediate danger, call 911. The crisis page lists more options.